TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
Study: NCT06630507

Intervention type: BEHAVIORAL
Intervention: Educational module
Description: 1 hour pre-recorded educational module created by Dr. Sharma.
Study: NCT06631703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group receiving Oral Colostrum Administiration
Description: Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
Study: NCT06631625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Intravenous Infusion
Description: Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and ketamine
Description: Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and dexmedetomidine infusion
Description: Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
Study: NCT06632132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial resistance Training in Hemodialysis Units
Description: The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos.
Study: NCT06377228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.
Study: NCT05926505

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Description: Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
Study: NCT05550831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Peripheral ablation of affected Morton´s Neuroma nerve endings by thermal dissipation by an electrode.
Study: NCT05741931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)
Description: The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
Study: NCT05371639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tian Ma Bian Chun Zhi Gan Tablets
Description: Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
Study: NCT05693883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
Study: NCT05623839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05829031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted music listening
Description: Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
Study: NCT05834569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Ibuprofen
Description: Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients in the control group will be administered equal amounts of normal saline at the same time points.
Study: NCT04248751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regeneten
Description: A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
Study: NCT06366074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watch-TEA group
Description: Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watch-TEA group
Description: Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance.
Study: NCT04970641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Good Things (3GT) Positive Psychology journaling activity
Description: Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
Study: NCT05634915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individual ATG
Description: Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
Study: NCT05147584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual fetal oxygen sensors
Description: Placement of both internal and external fetal oxygen sensors
Study: NCT05537896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Description: Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)
Study: NCT04696523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: air/oxygen
Description: Control group will be treated with air/oxygen
Study: NCT05803473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)
Description: For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Precision Pro Glucometer for glucose POC testing
Description: For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
Study: NCT05556226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154 Dose Formulation A
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154 Dose Formulation B
Description: Subcutaneous Injection
Study: NCT05942300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
Study: NCT06366074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered TEA device
Description: Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered TEA device
Description: Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance.
Study: NCT05235750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation writing
Description: Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
Study: NCT06292182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light
Description: daily application of near-infrared light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light
Description: daily application of near-infrared light
Study: NCT05258006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous demineralized dentin nanoparticles
Description: Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autogenous demineralized dentin nanoparticles
Description: Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
Study: NCT05128903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA714
Description: Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy
Study: NCT04906512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Tegaderm™ CHG I.V. Securement Dressing
Description: Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Tegaderm™ Transparent Film Dressing 1626W
Description: Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
Study: NCT06334042

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Chromium Level
Description: Measuring serum chromium levels from patients who admitted in intensive care unit.
Study: NCT04955730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Negative Pressure Wound Therapy is a single use NPWT that produces a negative pressure at -80 mmHg. Participants will have their fascia and skin closed in the same manner as the control arm participants, and will wear the NPWT dressing for 7 days after surgery.
Study: NCT06158490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061 15 mg
Description: Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061 30 mg
Description: articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
Study: NCT04934527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotect
Description: The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
Study: NCT06008080

Intervention type: DEVICE
Intervention: Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System
Description: Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
Study: NCT04977349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
Study: NCT05704647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986213 (Relatlimab-Nivolumab FDC)
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given by IV (vein)
Study: NCT05399433

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and venous blood
Description: A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis
Study: NCT05942300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
Study: NCT05567315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
Study: NCT04512378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Experiments for Intolerance of Uncertainty
Description: Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
Study: NCT06464640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up
Description: The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: E-book
Description: Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
Study: NCT06052358

Intervention type: DEVICE
Intervention: LAAC with Watchman FLX device
Description: LAAC with Watchman FLX device